Spero Therapeutics (SPRO) Operating Income (2016 - 2025)
Historic Operating Income for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.9 million.
- Spero Therapeutics' Operating Income rose 5742.48% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year decrease of 176073.08%. This contributed to the annual value of -$73.4 million for FY2024, which is 38877.74% down from last year.
- According to the latest figures from Q3 2025, Spero Therapeutics' Operating Income is -$7.9 million, which was up 5742.48% from -$2.4 million recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Operating Income ranged from a high of $54.5 million in Q4 2023 and a low of -$30.2 million during Q1 2022
- Over the past 5 years, Spero Therapeutics' median Operating Income value was -$14.7 million (recorded in 2025), while the average stood at -$10.7 million.
- As far as peak fluctuations go, Spero Therapeutics' Operating Income skyrocketed by 19734.2% in 2022, and later crashed by 86137.54% in 2024.
- Quarter analysis of 5 years shows Spero Therapeutics' Operating Income stood at -$27.5 million in 2021, then skyrocketed by 197.34% to $26.8 million in 2022, then soared by 103.41% to $54.5 million in 2023, then tumbled by 139.9% to -$21.7 million in 2024, then skyrocketed by 63.56% to -$7.9 million in 2025.
- Its Operating Income was -$7.9 million in Q3 2025, compared to -$2.4 million in Q2 2025 and -$14.7 million in Q1 2025.